Replies to post #6816 on Cel Sci Corporation (CVM)

[maverick1856]

CEL-SCI (NYSE: CVM) is the most undervalued Phase lll biotech in America.

CEL-SCI (NYSE: CVM) is the most undervalued Phase lll biotech in America. This turnaround aims to enroll 880 head and neck cancer patients in over 100 sites in at least 21 countries before yearend. Success in this global Phase III trial of its lead immunotherapy drug regime Multikine could be rewarded with a one day stock jump of $ billions. Other tantalizing possibilities exist for HPV and rheumatoid arthritis. Dreamer CEO Geert Kersten and his outstanding team are building a keeper.

http://archive.constantcontact.com/fs141/1101855435216/archive/1120223807599.html

credit Ducruacuteo11 for article find

[maverick1856]

A lawyer who is also married to a lawyer who is a former crime-fighting Assistant U.S. Attorney, Kersten dedicated five months of his life to prepare a $50 million arbitration suit for breach of contract, fraud in the inducement and common law fraud. He believes they have a very strong case. In June 2014 the arbitrator denied the CRO's motion to dismiss. If a settlement is not reached, a trial is scheduled to start on May 4th. If CEL-SCI wins, a final judgment could include hundreds of millions for punitive damages.